[{"id":"e098103f-75c1-4aa9-b386-41c1d51fb602","acronym":"MATCH","url":"https://clinicaltrials.gov/study/NCT03155620","created_at":"2021-01-18T15:33:32.929Z","updated_at":"2025-02-25T16:51:52.930Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","source_id_and_acronym":"NCT03155620 - MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2316","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-04"},{"id":"a896ec8e-9825-4531-a478-c93b653bba25","acronym":"","url":"https://clinicaltrials.gov/study/NCT02057133","created_at":"2021-01-17T17:28:58.622Z","updated_at":"2025-02-25T14:00:24.405Z","phase":"Phase 1","brief_title":"A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread","source_id_and_acronym":"NCT02057133","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • CDK4 • CDK6","pipe":" | ","alterations":" HR positive • HER-2 negative • EGFR positive","tags":["HER-2 • CDK4 • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • everolimus • tamoxifen • Perjeta (pertuzumab) • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane • samotolisib (LY3023414) • loperamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 03/10/2014","start_date":" 03/10/2014","primary_txt":" Primary completion: 03/15/2021","primary_completion_date":" 03/15/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-08-28"},{"id":"013fa224-7354-475f-bf22-774d9ee304d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03675893","created_at":"2021-01-18T18:01:44.633Z","updated_at":"2024-07-02T16:34:27.103Z","phase":"Phase 2","brief_title":"RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer","source_id_and_acronym":"NCT03675893","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • letrozole • zotatifin (eFT226) • metformin • samotolisib (LY3023414)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 12/24/2018","start_date":" 12/24/2018","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2024-06-11"},{"id":"6f199ca7-66c7-422b-8786-948a1a709536","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213678","created_at":"2021-01-18T15:51:26.276Z","updated_at":"2024-07-02T16:35:02.372Z","phase":"Phase 2","brief_title":"Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213678","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • TSC2 • TSC1","pipe":" | ","alterations":" PTEN expression • TSC1 mutation • TSC2 mutation","tags":["PTEN • TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression • TSC1 mutation • TSC2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/28/2017","start_date":" 11/28/2017","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-05-21"},{"id":"931391bf-b0d8-47a7-96c3-13986b5a3f13","acronym":"ExIST","url":"https://clinicaltrials.gov/study/NCT04032080","created_at":"2021-03-26T18:56:03.697Z","updated_at":"2024-07-02T16:35:37.448Z","phase":"Phase 2","brief_title":"LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer","source_id_and_acronym":"NCT04032080 - ExIST","lead_sponsor":"Baylor Research Institute","biomarkers":" ER","pipe":" | ","alterations":" ER negative","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prexasertib (ACR-368) • samotolisib (LY3023414)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 09/05/2019","start_date":" 09/05/2019","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 11/26/2022","study_completion_date":" 11/26/2022","last_update_posted":"2023-09-11"},{"id":"d9d3567e-a116-4764-b0c4-18eb2c09592c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02549989","created_at":"2021-01-18T12:20:10.264Z","updated_at":"2024-07-02T16:35:54.941Z","phase":"Phase 2","brief_title":"Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer","source_id_and_acronym":"NCT02549989","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PIK3CA • PTEN • AKT1 • PIK3R1 • PIK3R2","pipe":" | ","alterations":" PTEN deletion","tags":["PIK3CA • PTEN • AKT1 • PIK3R1 • PIK3R2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e samotolisib (LY3023414)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 03/23/2022","primary_completion_date":" 03/23/2022","study_txt":" Completion: 03/23/2022","study_completion_date":" 03/23/2022","last_update_posted":"2023-02-22"},{"id":"dee4abbf-b12e-40b5-a118-06cfe0d9020a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01655225","created_at":"2021-01-17T17:45:33.298Z","updated_at":"2024-07-02T16:36:13.381Z","phase":"Phase 1","brief_title":"A Study of LY3023414 in Participants With Advanced Cancer","source_id_and_acronym":"NCT01655225","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • CYP3A4","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Verzenio (abemaciclib) • pemetrexed • fulvestrant • letrozole • samotolisib (LY3023414) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 156","initiation":"Initiation: 07/31/2012","start_date":" 07/31/2012","primary_txt":" Primary completion: 04/04/2019","primary_completion_date":" 04/04/2019","study_txt":" Completion: 02/02/2022","study_completion_date":" 02/02/2022","last_update_posted":"2022-04-08"},{"id":"a7f30cb8-462c-4f77-a391-48ab885c8c71","acronym":"","url":"https://clinicaltrials.gov/study/NCT02124148","created_at":"2021-01-18T09:50:31.965Z","updated_at":"2024-07-02T16:36:47.033Z","phase":"Phase 1b","brief_title":"A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer","source_id_and_acronym":"NCT02124148","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • KRAS • ER • PIK3CA • PGR","pipe":" | ","alterations":" HER-2 overexpression • PIK3CA mutation • KRAS wild-type • RAS wild-type • ER negative • PGR negative","tags":["HER-2 • KRAS • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • PIK3CA mutation • KRAS wild-type • RAS wild-type • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • 5-fluorouracil • pemetrexed • prexasertib (ACR-368) • leucovorin calcium • samotolisib (LY3023414)"],"overall_status":"Completed","enrollment":" Enrollment 167","initiation":"Initiation: 06/18/2014","start_date":" 06/18/2014","primary_txt":" Primary completion: 02/13/2020","primary_completion_date":" 02/13/2020","study_txt":" Completion: 02/13/2020","study_completion_date":" 02/13/2020","last_update_posted":"2020-04-01"}]